Severe Bronchopulmonary Dysplasia Clinical Trial
Official title:
Safety and Efficacy of Aerosolized Albuterol in Mechanically Ventilated Infants With Bronchopulmonary Dysplasia (BDP)
Currently several dose schedules of Albuterol are administered via nebulization to infants in
the neonatal and infant intensive care unit (N/IICU). As Albuterol is not FDA approved for
this population (under 2 years) there is no standard recommended dose. Aerosolized Albuterol
is one of the most widely used therapies that are utilized for infants with chronic lung
disease. The common practice in the N/IICU is weight base dosing of all medications. This
contradicts the aerosol science recommendations, which advise not to titrate doses by weight
as the patient naturally self-regulates their dose according to the change in minute
ventilation with age. In addition, the wide use of aerosolized Albuterol in the infant with
Bronchopulmonary Dysplasia (BPD) has little current evidence of efficacy in this disease.
Understanding the appropriate dose for effective treatment as well as the indication for use
in the BPD population would provide the clinician with useful guidelines.
The investigators propose to analyze the safety and efficacy of aerosolized albuterol in
infants with BPD comparing the recommended dose per aerosolization literature with the common
dosing practices at The Children's Hospital of Philadelphia (CHOP) as well as placebo.
This is a randomized, blinded cross-over study of infants with a diagnosis of Severe BPD that are mechanically ventilated. Participants will receive 3 sets of treatment (2.5mg Albuterol, 1.25mg Albuterol, 3ml normal saline placebo), in random order. Each treatment will be administered every 4 hours for 24 hours. After a 6 hour washout phase, the next group of interventions will be applied. Following another wash-out phase, the final group of intervention will be applied. Pulmonary mechanics from the ventilator (e.g. airway compliance, airway resistance, tidal volume, peak inspiratory pressure, Forced Expiratory Flow at 75% of forced vital capacity, etc.) and the patient short term response to therapy (heart rate, blood pressure, heart rhythm) will be assessed for the duration of the treatment period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03392467 -
PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants
|
Phase 2 |